Skip To Main Content
Alison Barnes on Muck Rack

Alison Barnes

As seen in: Wiley Online Library, MDPI, Sydney Morning Herald, The Age, HuffPost UK, New York Law Journal, The Canberra Times, Cell Press, The Lancet, Brisbane Times and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Alison

Contact Alison, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

In Groundbreaking Decision, Third Circuit Finds No Constitutional Bar to Regulating the Distribution of 3D-Printed Gun Codes

|
By Eric Tirschwell, Alison Barnes
| New York Law Journal Verified
Ghost guns printed on a 3D printer on display at Manhattan District Attorney Alvin Bragg's office in June 2023. Photo: Emily Saul/ALM Imagine living in a state or a country in which anyone, with no background check and no age verification, could sit in their basement and download a computer file that would allow them to 3D print their own gun—no questions asked.
Open in Who Shared Issue with article?

5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study

|
By Michael EJ Lean, Wilma S Leslie, Alison Barnes
| The Lancet Verified
Research in context Evidence before this study Before undertaking this study, we searched the published literature in PubMed from inception to Dec 5, 2017, for evidence on remission of type 2 diabetes using all potential interventions.
Open in Who Shared Issue with article?

Investors Beware: Private Equity Firms Continue to Face Potential Liability Under the False Claims Act for Their Portfolio Companies’ Conduct | JD Supra

|
By Alison Barnes, Lee Turner Friedman, Ralph C. Mayrell
| JD Supra
Two years ago, the U.S. Department of Justice announced a focus on enforcing the False Claims Act against private equity firms based on their portfolio companies’ conduct.[1] That government focus remains strong: Private equity firms, and particularly those invested in health care and pharmaceutical businesses, continue to face exposure simply for knowing about — or recklessly disregarding — their portfolio company’s potential False Claims Act violations.
Open in Who Shared Issue with article?
See all 20 licensed articles (77 Total)